This HTML5 document contains 34 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05837/identifier/chemspider/
n4http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05837/identifier/pubchem-compound/
n5http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB05837/identifier/drugbank/

Statements

Subject Item
n2:DB05837
rdf:type
n5:Drug
n5:description
OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine. It is also more active than ara-C (another clinically used nucleoside analog) in all nine models and more active than either paclitaxel or cisplatin in the two lung xenograft models tested. This drug shows no unexpected toxicities; those observed appeared to be similar to other nucleoside agents.
n5:generalReferences
# Richardson F, Black C, Richardson K, Franks A, Wells E, Karimi S, Sennello G, Hart K, Meyer D, Emerson D, Brown E, LeRay J, Nilsson C, Tomkinson B, Bendele R: Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors. Cancer Chemother Pharmacol. 2005 Mar;55(3):213-21. Epub 2004 Nov 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15592840 # Roy AM, Tiwari KN, Parker WB, Secrist JA 3rd, Li R, Qu Z: Antiangiogenic activity of 4'-thio-beta-D-arabinofuranosylcytosine. Mol Cancer Ther. 2006 Sep;5(9):2218-24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16985055
n5:group
investigational
n5:indication
Investigated for use/treatment in solid tumors.
owl:sameAs
n4:DB05837
dcterms:title
OSI-7836
adms:identifier
n8:DB05837 n9:3037115 n10:2300942
n5:mechanismOfAction
OSI-7836 appears to have a different mechanism of tumor growth inhibition blocking the cell division cycle at a different point (the G2 phase) than gemcitabine. The mechanism of action involves phosphorylation to the triphosphate form followed by incorporation into cellular DNA, leading to cell death.
n5:IUPAC-Name
n6:271B4795-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B479B-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B479A-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4797-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4798-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4799-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B4794-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B47A1-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B47A2-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B479C-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B479D-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B479F-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B479E-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B47A0-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B47A7-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B47A9-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B47AA-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B47A6-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B47A5-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B47A8-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4796-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B47A3-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B47A4-363D-11E5-9242-09173F13E4C5